This website is intended for healthcare professionals only

Trending Topic

Close-up of a person rubbing their temple, depicting persistent headache pain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Migraines profoundly impact well-being, especially in children and adolescents. From 1990 to 2021, global pediatric migraine disability has increased, with particular vulnerability in females and adolescents aged 15–19.1 A 2023 meta-analysis found the prevalence of primary headache diagnosis in individuals aged 8–18 years to be 62%.2 The prevalence of a migraine diagnosis was 11%; 8% […]

José A. López García, EAN 2021: Clinical Development of SAN711, and its Potential to Treat Neuropathic Pain

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Aug 9th 2021

It was a pleasure to meet with José A. López García (University of Alcalá, Alcalá de Henares, Spain) to discuss the clinical development of SAN711, a selective GABAA α3 receptor positive allosteric modulator for the potential treatment of neuropathic pain.

The abstract entitled: ‘SAN711 a selective GABAA α3 receptor positive allosteric modulator as a novel treatment for trigeminal neuralgia ’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.

Questions:

  1. Could you tell us a little about SAN711, its selectivity and mechanism of action? (0:16)
  2. What are the objectives and design of the Phase 1 study of SAN711? (8:53)
  3. What are the intended clinical indications of SAN711? (10:55)

Disclosures: José A. López García has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch

Filmed as a highlight of the EAN Congress, Virtual 2021

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup